Jane Henderson, Chief Financial Officer at Apogee Therapeutics, Inc. (APGE), sold 1,500 shares at $80.00 ($120K) on 2025-12-19, disclosed to the SEC on 2025-12-23.
Scheduled sale ($120k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| APGE | SELL | 2026-04-03 | $170K | — | Filing → |
| APGE | SELL | 2026-03-27 | $170K | — | Filing → |
| APGE | SELL | 2026-03-04 | $140K | — | Filing → |